We tested the possibility that proteasome inhibition may reverse pre-existing cardiac hypertrophy and improve remodeling upon pressure overload. Mice were submitted to aortic banding, and followed up for three weeks. The proteasome inhibitor epoxomicin (0.5 mg/kg) or the vehicle were injected daily, starting two weeks after banding. At the end of the third week, vehicle-treated banded animals showed significant (P<0.05) increase in proteasome activity (PA), left ventricle/tibial length (LV/TL), myocyte cross-sectional area (MCA) and myocyte apoptosis compared to sham, and developed signs of heart failure, including increased lung weight/TL and decreased ejection fraction. Compared to that group, banded mice treated with epoxomicin showed no increase in PA, a lower LV/TL and MCA, reduced apoptosis, stabilized ejection fraction, and no signs of heart failure. Because overloadmediated cardiac remodeling largely depends on the activation of the proteasome-regulated transcription factor NF-κB, we tested whether epoxomicin would prevent this activation. NF-κB activity increased significantly upon overload, which was suppressed by epoxomicin. The expression of NF-κB-dependent transcripts, encoding collagen types I and III and the matrix metalloprotease MMP-2, increased (P<0.05) after banding, which was abolished by epoxomicin. Accumulation of collagen after overload, as measured by histology, was 75% lower (P<0.05) with epoxomicin compared to vehicle.
INTRODUCTION
The 26S proteasome is the main mechanism of degradation of intracellular proteins. It is made of two particles, the 19S cap, which binds and denatures the protein to be degraded, and the 20S core, which degrades the client protein through three proteolytic activities: trypsin-like, chymotrypsin-like, and caspase-like (45) . This degradation results in the production of peptides containing less than 20 aminoacids, which will be hydrolyzed completely by cytosolic peptidases.
Proteasome-mediated proteolysis has been extensively characterized in skeletal muscle, in conditions of muscle wasting, atrophy and cachexia (8, 39, 51) . However, a role for the proteasome in controlling cardiac cell mass remains largely unknown. Recent evidence shows that the proteasome may be involved in cardiac stress. For instance, several reports have shown the beneficial effects of proteasome inhibitors in preventing the damage resulting from myocardial ischemia/reperfusion (3, 32, 43) . However, limited information is available about the role of the proteasome in the cardiac response to stress induced by overload.
The goal of the present study was to test whether manipulation of proteasome activity might be a tool for the hypertrophied heart in terms of regression of pre-existing hypertrophy and prevention of cardiac remodeling. Our underlying hypothesis is that a regulation of proteasome activity participates in cardiac hypertrophy, contractile dysfunction and ventricular remodeling following pressure overload. Several lines of evidence support that possibility. First, it was shown that proteasome expression and activity are increased at the onset of pressure overload (13) . Second, it was shown recently that proteasome inhibition also prevents the pro-hypertrophic effect of growth agonists in isolated cardiac myocytes (23, 37) . In addition, a major component of overload-induced cardiac dysfunction is the accumulation of extracellular matrix by remodeling (7, 35) , which is associated with the activation of the inducible transcription factor NF-κB (17) . The activity of NF-κB is regulated by the proteasome (22) , and a previous study conducted in rat cardiac fibroblasts showed that proteasome inhibition blocks NF-κB activation and subsequent collagen synthesis (38) . Taking these observations together, proteasome inhibitors, when administered after the onset of pressure overload, could not only improve contractile function by limiting cardiac cell hypertrophy, but also reverse remodeling by preventing the NF-κB-mediated accumulation of collagen. Accordingly, our objective was to examine the consequence of proteasome inhibition on cardiac function and remodeling in the overloaded heart.
METHODS

Animal model
Experiments were performed on male, 3-to 4-month old 129SVJ mice. Proteasome inhibition was performed with epoxomicin (Peptide International, Louisville, KY), a specific inhibitor of the β5 protein responsible for the chymotryptic activity of the 20S core of the proteasome (30, 40) . The specificity of the inhibitor is further supported by the fact that the effects of epoxomicin can be reproduced by lactacystin, another proteasome inhibitor but with a different chemical structure (13, 23) . We also showed that epoxomicin does not affect chymotryptic enzymes not related to the proteasome (23) . Epoxomicin was diluted in saline/10% DMSO and injected at a daily dose of 0.5mg/kg intraperitoneally (ip) for a duration of one week, consistent with our previous studies (13, 23) . No complications and/or side effects related to treatment with epoxomicin were observed.
Controls were injected with the vehicle only. Aortic banding was performed on anesthetized mice (ketamine 65 mg/ kg, xylazine 1.2 mg/kg, and acepromazine 2.17 mg/kg) (13) , with a 7-0 braided polyester suture tied around the aorta against a 28-gauge needle. No complication or mortality was observed after banding, and all operated mice were included in the experimental groups. Shams underwent surgery without constriction. LV function was measured by 2D echocardiography (Accuson 256, 13 MHz probe). The left ventricle/tibial length (LV/TL) and the lung weight/TL (LW/TL) ratios were measured. The investigation conforms with the Guide for the care and use of laboratory animals published by the US National Institutes of Health (NIH publication No. 85-23, revised 1996) , and the animal protocol used in this study was approved by our institutional IACUC committee.
Immunoblotting
Total protein extraction was performed at 4 o C in a lysis buffer (25 mmol/L Tris-HCl at pH 8.0, 150 mmol/L NaCl, 15 mmol/L KCl, 1 mmol/L EDTA, 1 mmol/L DTT, 0.5% Triton X-100 and 5% glycerol) supplemented with protease, kinase and phosphatase inhibitors, followed by centrifugation at 12,000 x g for 20 min at 4 o C. All the samples were denatured by boiling, resolved on SDS-PAGE gels, and transferred to membranes. Primary antibodies were added at the recommended dilution and incubated overnight. Antibodies against the proteasome components were from Biomol (Plymouth, PA). Other antibodies were from Santa Cruz (Santa Cruz, CA). Detection was performed by chemiluminescence.
Proteasome assay
Proteasome activity was measured from 25 µg of total protein extracts added to 1 mL assay buffer (25 mmol/L HEPES at pH 7.5, 0.5 mmol/L EDTA) containing 40 µmol/L of the fluorogenic substrate Suc-LLVY-AMC (Boston Biochem, Cambridge, MA) and incubated at 37 0 C for 2 hours, in presence of different concentrations of ATP (23), followed by fluorescence measurement (Turner Designs, Sunnyvale, CA) (4). This substrate is specific for the chymotryptic activity of the proteasome, and does not interfere with the tryptic or caspase-like activities of the organelle (29) . The tryptic activity was measured from 10 µg proteins incubated under the same conditions with the substrate Boc-Leu-Arg-Arg-AMC (Biomol, Plymouth, PA).
NF-κB activity
The activity of the transcription factor NF-κB was measured with the Trans AM Assay Kit (Active Motif, Carlsbad, CA), an ELISA-based system that detects the binding of NF-κB to the immobilized DNA consensus binding site (16) . The binding reaction was carried out for one hour at room temperature upon addition of 30 µg of total protein extract and in presence of an antibody recognizing the NF-κB subunit p65. Binding activity was detected by spectrophotometry.
Histopathology
Samples were fixed in 10% formalin and cut in 7 mm-thick sections. Tissue sections were stained with Masson's trichrome to identify extracellular matrix, or with Picric Acid Sirius Red to identify collagen (27) . The surface of tissue section covered by extracellular matrix or collagen was measured on a Nikon E800 Eclipse microscope by video-based Metamorph Image analyzer system (Universal Imaging Corporation, Westchester, PA), and reported as a percentage of the total surface of the tissue section. Myocyte cross sectional area was determined on digitized images of TRITClabeled wheat germ agglutinin stained sections, as before (13) . Myocyte outlines were traced and the cell areas measured using Image-ProPlus Software System (Silver Springs, MD). At least 100 myocytes were measured in each region. TUNEL was performed as described (11) 
Quantitative PCR
Specific primers and probes (derived with FAM and TAMRA) (19) were designed for the transcripts of collagen type I and collagen type III, and of the matrix metalloprotease-2 using the Primer Express software (Applied Biosystems, Foster City, CA). Total RNA was extracted by the phenol-chloroform method using the Tri-Reagent (Sigma Aldrich, St. Louis, MO) (6). For each measurement, the mRNA of interest was reverse-transcribed from 60 ng of total RNA with the TaqMan RT kit (Applied Biosystems, Foster City, CA), and used for quantitative PCR (40 cycles of a 10 sec-step at 95 o C and a 1 min-step at 60 o C) using the TaqMan PCR mix (Applied Biosystems) on a 7300 ABI-Prizm Sequence Detector (Applied Biosystems, Foster City, CA). Standards were prepared for each transcript of interest from its PCR-amplified cDNA after ligation of the T7 promoter (Ambion, Austin, TX) (12) . Due to the variation in loading, transcripts were reported to cyclophilin, used as a housekeeping gene (44) .
Cell culture
Cardiac myocytes were prepared from 1 day-old Wistar rats as before (10) 
Statistical analysis
Results are presented as the mean ± SEM for the number of animals indicated in each Figure   legend . We used the Student's t test for two-group comparison. Two-way analysis of variance (ANOVA) with post-hoc Bonferroni correction was used for multi-group comparison when necessary.
A value of P<0.05 was considered significant.
RESULTS
Proteasome activation after initiation of pressure overload
We first measured the changes in proteasome activity in response to pressure overload using total heart extracts from mice banded for one week compared to sham animals. Because the normal activity and assembly of the 19S and 20S proteasome subunits require energy (40), the activity assay was performed in presence of different concentrations of ATP. As expected (41), addition of ATP progressively increased the proteasome activity until reaching a plateau (Figure 1a ). At all concentrations of ATP, the proteasome activity was significantly higher in banded mice compared to sham ( Figure 1a ). In order to verify that proteasome activation during hypertrophy takes place in cardiac cells, cardiac myocytes were isolated from mice hearts subjected to one week banding. As shown in Figure 1b , cardiac myocytes showed an increased proteasome activity after banding that was comparable to the increase found in total heart extracts.
Proteasome inhibition decreases pre-existing cardiac hypertrophy
Mice were followed up to three weeks following aortic banding to determine the dynamic adaptation of proteasome activity, and cardiac structure and function in response to pressure overload. Vehicle-treated banded mice showed a progressive increase in proteasome activity together with an increase in left ventricle/tibial length (LV/TL) ratio (6.2±0.3 in sham versus 9.9±0.4 three weeks after banding; P<0.01), reflecting cardiac hypertrophy ( Figure 2 ). Between the second and third week after banding, these mice also developed signs of heart failure, including an increase in lung weight/tibial length (LW/TL) ratio (10.0±0.3 in sham versus 13.6±0.7 three weeks after banding; P<0.01) and a decrease in ejection fraction ( Figure 2 ).
Based on these data, an additional group of mice was treated with the proteasome inhibitor epoxomicin, initiated two weeks after banding, the time point at which cardiac function starts to deteriorate ( Figure 2 ). Mice were treated for one week with epoxomicin (0.5 mg/kg daily, ip) or with the vehicle. All mice were analyzed at the end of the third week after banding. Treatment with epoxomicin suppressed the increase in proteasome activity found in hearts from banded mice compared to shams, and it also reduced the LV/TL (Figure 2 ). Further deterioration of cardiac function during the third week of overload, both in terms of LW/TL and ejection fraction, was prevented by epoxomicin treatment (Figure 2 ). Therefore, epoxomicin reduces pre-existing hypertrophy and stabilizes ejection fraction. We showed before (13, 23 ) that a one-week treatment with epoxomicin in sham-operated mice does not affect LV/TL, LW/TL or ejection fraction.
Proteasome inhibition decreases morphological damage by pressure overload
To begin elucidating the molecular mechanisms by which epoxomicin prevents the deterioration of cardiac function after banding, we first compared the morphology of hearts treated with vehicle or with the proteasome inhibitor on tissue sections stained with Masson's trichrome.
Compared to shams, vehicle-treated banded hearts showed an accumulation of extracellular matrix that increased progressively, covering 6.6% of the myocardial cross-sectional area after two weeks of pressure overload, and 13.3% after three weeks (Figure 3a 
Regulation of collagen transcripts by proteasome inhibition
To determine how proteasome inhibition prevents collagen accumulation in the overloaded heart, we measured by quantitative PCR the expression of genes encoding collagen type I and type III. Compared to sham-operated animals, the expression of these genes increased by about 3-to 5-fold after three weeks banding in vehicle-treated animals ( Figure 4a) . However, such increase triggered by pressure overload was totally prevented in presence of epoxomicin (Figure 4a ).
We examined next which transcriptional mechanism might be involved to prevent the activation of the genes encoding collagen upon pressure overload. An important activator of collagen gene expression upon cardiac stress is the proteasome-regulated heterodimeric (p50/p65) transcription factor NF-κB (38) , which is activated during myocardial hypertrophy (24, 42) . (Figure 4d ).
In epoxomicin-treated banded hearts, however, IκBα protein expression was comparable to that found in sham animals ( Figure 4d ).
Sequential effects of proteasome inhibitors in the overloaded heart
It could be argued that the decreased activity of NF-κB in hearts from mice treated with epoxomicin after banding is the consequence, rather than the cause, of decreased hypertrophy. To address that potential limitation, mice were treated with a single dose of epoxomicin two weeks after banding and sacrificed 24 hours later. In that group, the proteasome activation induced by pressure overload was already abolished after a single injection of epoxomicin ( Figure 5 ). The increase in NF-κB activity was also reduced by 40-50% ( Figure 5 ). However, heart mass (LV/TL) and cardiac contractility (ejection fraction) were not significantly affected compared to vehicle-treated banded hearts ( Figure 5) . Similarly, collagen transcript expression was unchanged compared to vehicletreated mice ( Figure 5) . Therefore, the reduction of NF-κB activity upon epoxomicin treatment following overload precedes any change in heart mass and remodeling, and is not a mere consequence of decreased hypertrophy.
The effects of epoxomicin are independent from apoptosis
Proteasome inhibitors are now used in the treatment of certain forms of cancer for their cytotoxic and pro-apoptotic effect (31) . The decreased heart mass observed after epoxomicin treatment could be due to myocyte apoptosis. Therefore, we tested whether epoxomicin would induce apoptosis in the heart. Myocyte apoptosis was measured by TUNEL in hearts from mice submitted to 3-week aortic banding with or without epoxomicin. Compared to sham, apoptosis increased by about 4-fold in hearts after three weeks banding in presence of the vehicle, which was reduced by half in the group treated with epoxomicin for one week (Figure 6a ). To further confirm that epoxomicin treatment after aortic banding reduces cardiac cell size, myocyte cross-sectional area was measured in the four experimental groups. A significant increase in cross-sectional area was observed after three weeks banding in vehicle-treated mice, which was significantly reduced by 50% upon epoxomicin treatment (Figure 6a) . Therefore, the reduction in LV/TL upon epoxomicin treatment in banded hearts corresponds to reduced cardiac cell size, and not to increased apoptosis.
To further address the potential toxicity of epoxomicin in the heart in vivo, sham mice were treated daily for one week with different doses of epoxomicin, ranging from 0.5 to 5.0 mg/kg. At the end of the protocol, myocyte apoptosis was measured by TUNEL. Epoxomicin treatment significantly increased the number of TUNEL-positive myocytes at the highest dose tested, i.e., 5.0 mg/kg, but not at the dose (0.5 mg/kg) used in our study (Figure 6b ). Proteasome activity was measured in these different groups. Epoxomicin binds the β5 subunit of the 20S core particle and therefore inhibits only the chymotryptic activity of the proteasome (40) . At the dose used in our study (0.5 mg/kg), that activity was decreased by about 50%, whereas a maximal 80% inhibition was observed at higher doses ( Figure 6b ). Epoxomicin did not affect the tryptic activity of the proteasome, except at the dose of 5.0 mg/kg (Figure 6b) . Therefore, the increased apoptosis observed at 5.0 mg/kg may result from a toxic effect, rather than a pharmacological effect, when the drug concentration is too high to remain specific for the chymotryptic activity of the proteasome.
The relative toxicity of epoxomicin compared to well-known pro-apoptotic agents was further investigated in vitro, using isolated rat cardiac myocytes. We showed before that, in such model, concentration of the drug (Figure 6c ). However, addition of 100 µM H 2 O 2 to the myocyte preparation, used as a positive control, increased apoptosis to a much larger extent than did epoxomicin ( Figure   6c ). The loss of proteasome activity in the H 2 O 2 group probably reflects the increased death rate of the myocytes rather than a true inhibition of the proteasome, because this group does not show an accumulation of poly-ubiquitylated proteins (Figure 6c ). These data, taken together with the data obtained in vivo (Figure 6b ), confirm that the proteasome can be significantly inhibited without necessarily inducing apoptosis in myocytes.
DISCUSSION
The main finding of our study is the observation that treatment of the overloaded heart with proteasome inhibitors started after the onset of hypertrophy leads to a stabilization of contractile parameters, a regression of pre-existing hypertrophy, a decrease in lung weight to tibial length and a decrease in the accumulation of interstitial collagen. Therefore, proteasome inhibition can reduce preexisting hypertrophy and ventricular remodeling. The proposed mechanism that is discussed below is summarized in Figure 7 . Epoxomicin is considered one of the most specific inhibitors of the proteasome (40) . Not only does it target only the chymotryptic activity of the proteasome (30), but it is also devoid of any inhibitory effect on proteasome-independent chymotryptic enzymes (23) . In addition, the effects of epoxomicin in the heart can be reproduced by lactacystin (13, 23) , a proteasome inhibitor with lower specificity and displaying a totally different chemical structure than epoxomicin (9, 28, 40) .
It is usually considered that cardiac hypertrophy represents an adaptive response to pressure overload that progressively evolves into a maladaptive condition due to increased wall stress, Ca 2+ overload, increased energetic demand and apoptosis among other factors (5) . In that context, it may seem counterintuitive to prevent or reduce hypertrophy in the face of overload. However, several recent studies support that concept. In one example, increased wall stress upon banding in mice with genetic deletions preventing the development of hypertrophy was not accompanied by functional deterioration of the heart, at the opposite of the corresponding wild type mice (15) . In addition, treatment with rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), before the induction of pressure overload decreases significantly the development of hypertrophy without impairing contractile function (47) , whereas treatment with rapamycin after induction of overload leads to a regression of hypertrophy and to a stabilization of contractility (36) . Our previous data demonstrated that epoxomicin prevents hypertrophy when administered before the onset of pressure overload (13) , and the present study shows that it also reverses pre-existing hypertrophy in the overloaded heart and stabilizes contractile function. Whether cardiac function may be actually improved by epoxomicin would require a longer duration of treatment. It may seem counterintuitive that blocking a pathway of proteolysis will reduce rather than increase cardiac mass. This paradox may be explained by the fact that proteasome inhibition blocks an inducible mechanism of cell growth activated by NF-κB in conditions of cardiac stress ( Figure 7 ). In addition, one of our previous studies suggests that proteasome inhibition is accompanied by a blockage of translation initiation in order to reach a new steady state between protein synthesis and degradation (23) . Whether such observation can be extended beyond a rodent model will be the subject of future investigations. In addition, proteasome inhibition can reverse stable, chronic cardiac hypertrophy in absence of overload, also without affecting cardiac contractility (23) , and it decreases chronic isoproterenol-induced hypertrophy, although cardiac function and proteasome activity were not measured in that case (50) .
A major component of the ventricular remodeling following pressure overload is the accumulation of extracellular matrix, and in particular of collagen. Accumulation of collagen in the failing heart affects cardiac geometry and wall stress, and thereby alters myocyte function and size (25) . Our experiments show that collagen accumulation in the overloaded heart can be blunted by proteasome inhibitors, most likely through a down-regulation of NF-κB activity. In the normal heart, NF-κB activity is prevented by its specific inhibitor, IκBα (22) , which is constitutively produced and which binds NF-κB, thereby preventing the activation of the transcription factor. Multiple pathways mediating the cellular stress triggered by pressure or volume overload can activate IκBα kinases, which phosphorylate IκBα (21) . Upon phosphorylation, IκBα is tagged for ubiquitylation and proteasomal degradation, thereby freeing NF-κB, which becomes transcriptionally active (21).
Although NF-κB is not sufficient in itself to activate collagen transcription (38) , it can do so indirectly through increased expression of matrix metalloproteases (MMPs), and in particular of the gelatinases MMP-2 and MMP-9 (38) . Among the multiple forms of MMPs, the gelatinases MMP-2 and MMP-9 are expressed both in cardiac fibroblasts and in myocytes, and can degrade several types of collagen (including the types I and III) (48) . It could be argued that, because the function of MMPs is to degrade collagen, prevention of MMP expression by proteasome inhibitors should rather increase collagen density in myocardial tissue. However, the dissociation of collagen bundles by MMPs automatically leads to additional collagen synthesis through transcriptional activation of the corresponding genes (26). This conclusion is supported by observations in genetically-modified mouse models. Deletion of MMP-9 decreases ventricular remodeling after myocardial infarction by limiting collagen accumulation, whereas deletion of MMP-2 produces a similar effect in a model of pressure overload (14, 34) . Taken these data together, we propose that a repression of NF-κB activation upon pressure overload by proteasome inhibitors blocks the transcriptional activation of MMPs, thereby preventing the transcription of genes encoding collagen isoforms ( Figure 7 ). Our observations support a central role for NF-κB repression upon treatment with proteasome inhibitors because short-term treatment with epoxomicin led to a decreased activity of NF-κB before any change in heart mass, ventricular function or ventricular remodeling could be detected.
Epoxomicin treatment did not induce cardiac toxicity, as assessed by the improvement of cardiac contractile function and the absence of apoptosis. Acute toxicity of proteasome inhibitors is the subject of intense debate, especially because of the pro-apoptotic and therapeutic effect of the proteasome inhibitor PS341 or Bortezomib (Velcade®) in cancer (1) . Bortezomib is particularly useful in the treatment of hematological malignancies, such as myeloma, macroglobulinemia and lymphoma (31) . The therapeutic effect of Bortezomib is also related to an inhibition of NF-κB, particularly in myeloma, a tumor in which this transcription factor controls the expression of interleukin-6, which is critical for cell growth and adhesion, as well as angiogenesis (2) . Velcade® is particularly efficient in cancers from secretory cells. These cells rely heavily on the endoplasmic reticulum (ER) for protein synthesis and secretion, but this high rate of translation automatically includes a large proportion of misfolded and denatured proteins that must be destroyed. An accumulation of unfolded proteins in the ER results in the translocation of nascent denatured peptidic chains from the ER back to the ubiquitinproteasome system, a process known as ER-associated degradation (ERAD) (33) . In the presence of proteasome inhibitors, ERAD is blocked, leading to a rapid accumulation of unfolded proteins in the ER, which triggers the "unfolded protein response" resulting in the death of the tumor cell by apoptosis (31, 53) .
These observations in myeloma raise the question as to why epoxomicin is not more toxic for normal cells, including cardiac myocytes. It is possible that different effects result from proteasome inhibition depending on the cell type that is targeted. For example, proteasome inhibition promotes cell survival in neurons (52) or endothelial cells (49) . The proteasome cleaves the client protein through at least three different proteases, including a trypsin-like (cutting the peptidyl bond involving basic amino acids), a chymotrypsin-like (for hydrophobic amino acids), and a caspase-like or peptidylglutamyl hydrolase (acid amino acids) (22) . Epoxomicin is highly specific for the chymotryptic activity (30) , and therefore does not totally inhibit the proteasome. It is estimated that epoxomicin can block the proteolytic activity of the proteasome by no more than 30-40% (30) , which may explain why proteasome inhibitors have limited toxicity for normal cells with low secretory function. In a doseresponse experiment, we measured whether one week daily treatment with epoxomicin would increase myocyte apoptosis, however no difference was observed between the dose used in our study and the vehicle. Although the measurement of apoptosis by TUNEL shows only what happens in the heart at one specific time point, high doses of epoxomicin induced apoptosis after one week, and the comparison of the chymotryptic and tryptic activities in these samples supports that such proapoptotic effect results from a toxic effect of the molecule rather than from a pharmacological consequence of proteasome inhibition.
In conclusion, proteasome inhibition after the onset of pressure overload prevents further deterioration of cardiac function, reduces cardiac cell size and limits ventricular remodeling. These effects of proteasome inhibitors seem largely due to an inhibition of the NF-κB pathway mediating an accumulation of interstitial collagen and further cardiac remodeling. These results support a potential therapeutic role for proteasome inhibition in the treatment of cardiac hypertrophy.
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